Cells develop a heterogeneous response to KRAS inhibitors, bypassing their anti-growth effects by producing more of the protein that does not bind the inhibitor.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Insights into protein post-translational modification landscapes of individual human cells by trapped ion mobility time-of-flight mass spectrometry
Nature Communications Open Access 25 November 2022
-
Drugging KRAS: current perspectives and state-of-art review
Journal of Hematology & Oncology Open Access 25 October 2022
-
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Journal of Experimental & Clinical Cancer Research Open Access 19 January 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013).
Canon, J. et al. Nature 575, 217–223 (2019).
Hallin, J. et al. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-19-1167 (2019).
Ruess, D. A. et al. Nat. Med. 24, 954–960 (2018).
Mainardi, S. et al. Nat. Med. 24, 961–967 (2018).
Misale, S. et al. Clin. Cancer Res. 25, 796–807 (2019).
Xue, J.Y. et al. Nature https://doi.org/10.1038/s41586-019-1884-x (2020).
Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Science 351, 604–608 (2016).
Patricelli, M. P. et al. Cancer Discov. 6, 316–329 (2016).
Prahallad, A. et al. Nature 483, 100–103 (2012).
Shaffer, S. M. et al. Nature 546, 431–435 (2017).
Hata, A. N. et al. Nat. Med. 22, 262–269 (2016).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
A.N.H. has received research funding from Amgen, Pfizer, Roche/Genentech, Eli Lilly, Novartis and Relay Therapeutics. A.T.S. has served as a compensated consultant or received honoraria from Achilles, Archer, ARIAD, Bayer, Blueprint Medicines, Chugai, Daiichi Sankyo, EMD Serono, Foundation Medicine, Genentech/Roche, Guardant, Ignyta, KSQ Therapeutics, LOXO, Natera, Novartis, Pfizer, Servier, Syros, Taiho Pharmaceutical, Takeda and TP Therapeutics; has received research (institutional) funding from Daiichi Sankyo, Ignyta, Novartis, Pfizer, Roche/Genentech and TP Therapeutics; has served on the Board of Directors of Syros Pharmaceuticals; and is currently an employee of Novartis.
Rights and permissions
About this article
Cite this article
Hata, A.N., Shaw, A.T. Resistance looms for KRASG12C inhibitors. Nat Med 26, 169–170 (2020). https://doi.org/10.1038/s41591-020-0765-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-020-0765-z
This article is cited by
-
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Journal of Experimental & Clinical Cancer Research (2022)
-
Drugging KRAS: current perspectives and state-of-art review
Journal of Hematology & Oncology (2022)
-
Insights into protein post-translational modification landscapes of individual human cells by trapped ion mobility time-of-flight mass spectrometry
Nature Communications (2022)
-
The metabolic landscape of RAS-driven cancers from biology to therapy
Nature Cancer (2021)
-
Structure-based inhibitor design of mutant RAS proteins—a paradigm shift
Cancer and Metastasis Reviews (2020)
